NEW YORK (GenomeWeb) – Canaccord and William Blair have upgraded their ratings on Quidel’s shares to Buy and Outperform, respectively, based on its acquisition of Alere's Triage B-type natriuretic peptide assay and cardiovascular and toxicology diagnostic assets, announced yesterday.

Quidel agreed to pay $400 million for the assets and $40 million in contingent consideration. It expects the deal to close by Sept. 20.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.